Lung Cancer

KRAS-targeted therapy shows promising first results in NSCLC

Until now KRAS-positive lung cancers have been considered ‘undruggable’ but early results with the first targeted therapy have shown promising and durable response rates. Presented at the World Congress on Lung Cancer 2019 meeting in Barcelona, the phase 1 study results for the novel KRAS G12C Inhibitor AMG 510 showed it was effective and well ...

Already a member?

Login to keep reading.

© 2022 the limbic